{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:00:57Z","timestamp":1792684857754,"version":"4.5.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016045","name":"King Khalid University Research Center for Advanced Material Science","doi-asserted-by":"publisher","award":["CL\/CO\/A\/8"],"award-info":[{"award-number":["CL\/CO\/A\/8"]}],"id":[{"id":"10.13039\/501100016045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.yexcr.2025.114516","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T20:03:11Z","timestamp":1741636991000},"page":"114516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders"],"prefix":"10.1016","volume":"447","author":[{"given":"Farag M.A.","family":"Altalbawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zarrina","family":"Babamuradova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalji","family":"Baldaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhayveer","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamred Udham","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhas","family":"Ballal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sabarivani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadhil Faez","family":"Sead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubyat","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3873-4565","authenticated-orcid":false,"given":"Mohammad Y.","family":"Alshahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2025.114516_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imbio.2015.08.005","article-title":"Blimp-1\/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells","volume":"221","author":"Kim","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.yexcr.2025.114516_bib2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0065-2776(08)00004-7","article-title":"The SLAM and SAP gene families control innate and adaptive immune responses","volume":"97","author":"Calpe","year":"2008","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0952-7915(03)00041-4","article-title":"The SLAM family of immune-cell receptors","volume":"15","author":"Veillette","year":"2003","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib5","doi-asserted-by":"crossref","DOI":"10.1007\/s002510000274","article-title":"Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily","volume":"52","author":"Boles","year":"2001","journal-title":"Immunogenetics"},{"key":"10.1016\/j.yexcr.2025.114516_bib6","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib7","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1038\/s41375-020-0860-7","article-title":"Soluble SLAMF7 is a predictive biomarker for elotuzumab therapy","volume":"34","author":"Suzuki","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2025.114516_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/cts.12532","article-title":"Mechanisms of action and clinical development of elotuzumab","volume":"11","author":"Ritchie","year":"2017","journal-title":"Clinical and translational science"},{"key":"10.1016\/j.yexcr.2025.114516_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.gene.6364453","article-title":"Association of LY9 in UK and Canadian SLE families","volume":"9","author":"Graham","year":"2008","journal-title":"Gene Immun."},{"key":"10.1016\/j.yexcr.2025.114516_bib10","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.3390\/cancers12071755","article-title":"Roles of NK cell receptors 2B4 (CD244), CS1 (CD319), and LLT1 (CLEC2D) in cancer","volume":"12","author":"Buller","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.yexcr.2025.114516_bib11","series-title":"Collisions at Sqrt (S)= 7 TeV","article-title":"Measurements of the upsilon (1S), upsilon (2S), and upsilon (3S) differential cross sections","author":"collaboration","year":"2015"},{"key":"10.1016\/j.yexcr.2025.114516_bib12","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.4049\/jimmunol.167.10.5517","article-title":"Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family","volume":"167","author":"Bouchon","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib14","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/26683","article-title":"The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM","volume":"395","author":"Sayos","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2025.114516_bib15","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/eji.200424917","article-title":"Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine\u2010based switch motifs","volume":"34","author":"Lee","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib16","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00011-013-0632-1","article-title":"CS1 (SLAMF7) inhibits production of proinflammatory cytokines by activated monocytes","volume":"62","author":"Kim","year":"2013","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-065X.2009.00824.x","article-title":"Importance and mechanism of \u2018switch\u2019function of SAP family adapters","volume":"232","author":"Veillette","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.yexcr.2025.114516_bib20","series-title":"Molecular and Cellular Biology","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","author":"Guo","year":"2015"},{"key":"10.1016\/j.yexcr.2025.114516_bib21","doi-asserted-by":"crossref","first-page":"7996","DOI":"10.4049\/jimmunol.175.12.7996","article-title":"The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase C\u03b3 signaling pathways in human NK cells","volume":"175","author":"Tassi","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092184","article-title":"Fine specificity and molecular competition in SLAM family receptor signalling","volume":"9","author":"Wilson","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.yexcr.2025.114516_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1084\/jem.20132038","article-title":"EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase C\u03b3, Ca++, and Erk, leading to granule polarization","volume":"211","author":"P\u00e9rez-Quintero","year":"2014","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexcr.2025.114516_bib24","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4049\/jimmunol.2000300","article-title":"SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment","volume":"206","author":"O'Connell","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib25","doi-asserted-by":"crossref","first-page":"460","DOI":"10.21147\/j.issn.1000-9604.2022.05.07","article-title":"Myeloid checkpoints for cancer immunotherapy","volume":"34","author":"Qian","year":"2022","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.tcb.2004.10.005","article-title":"Integrins: versatile integrators of extracellular signals","volume":"14","author":"Colognato","year":"2004","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.yexcr.2025.114516_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-065X.2009.00841.x","article-title":"The expanding roles of ITAM adapters FcR\u03b3 and DAP12 in myeloid cells","volume":"232","author":"Hamerman","year":"2009","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.yexcr.2025.114516_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coi.2015.11.003","article-title":"SLAM family receptors in normal immunity and immune pathologies","volume":"38","author":"Wu","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.yexcr.2025.114516_bib30","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical impact of serum soluble SLAMF7 in multiple myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.yexcr.2025.114516_bib31","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.3390\/curroncol30090573","article-title":"SLAMF7 as a promising immunotherapeutic target in multiple myeloma treatments","volume":"30","author":"Chu","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib32","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41375-019-0525-6","article-title":"Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7","volume":"34","author":"Kikuchi","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2025.114516_bib33","first-page":"1637","article-title":"CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib34","first-page":"1329","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.yexcr.2025.114516_bib35","doi-asserted-by":"crossref","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating multiple myeloma in the context of the bone marrow microenvironment","volume":"29","author":"Ho","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-016-0284-z","article-title":"Elotuzumab for the treatment of multiple myeloma","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib37","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexcr.2025.114516_bib38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","article-title":"Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib39","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2018.014","article-title":"Elotuzumab for the treatment of relapsed or refractory multiple myeloma, with special reference to its modes of action and SLAMF7 signaling","volume":"10","author":"Taniwaki","year":"2018","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"10.1016\/j.yexcr.2025.114516_bib40","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/2040620716657993","article-title":"Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab","volume":"7","author":"Einsele","year":"2016","journal-title":"Therapeutic advances in hematology"},{"key":"10.1016\/j.yexcr.2025.114516_bib41","article-title":"Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma","author":"Yee","year":"2024","journal-title":"Blood Advances"},{"key":"10.1016\/j.yexcr.2025.114516_bib42","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2025.114516_bib43","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.yexcr.2025.114516_bib44","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40262-017-0585-6","article-title":"The clinical pharmacology of elotuzumab","volume":"57","author":"Passey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.yexcr.2025.114516_bib45","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib46","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2025.114516_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2019-130277","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.yexcr.2025.114516_bib48","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib49","first-page":"552","article-title":"A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma, Blood","volume":"120","author":"Zonder","year":"2012","journal-title":"The Journal of the American Society of Hematology"},{"key":"10.1016\/j.yexcr.2025.114516_bib50","series-title":"CS1 Targeted Chimeric Antigen Receptor-Modified T Cells","author":"Wang","year":"2023"},{"key":"10.1016\/j.yexcr.2025.114516_bib51","first-page":"2838","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.yexcr.2025.114516_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008769","article-title":"Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma","volume":"12","author":"Korst","year":"2024","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10.1016\/j.yexcr.2025.114516_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"British journal of cancer"},{"key":"10.1016\/j.yexcr.2025.114516_bib54","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.yexcr.2025.114516_bib55","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.yexcr.2025.114516_bib56","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1002\/cai2.140","article-title":"Breast cancer immunotherapy: realities and advances","volume":"3","author":"Medina","year":"2024","journal-title":"Cancer Innovation"},{"key":"10.1016\/j.yexcr.2025.114516_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2022.13553","article-title":"Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer","volume":"24","author":"Assidi","year":"2022","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.yexcr.2025.114516_bib58","doi-asserted-by":"crossref","first-page":"a013359","DOI":"10.1101\/cshperspect.a013359","article-title":"N-linked protein glycosylation in the endoplasmic reticulum","volume":"5","author":"Breitling","year":"2013","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.yexcr.2025.114516_bib59","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41467-018-04313-6","article-title":"STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion","volume":"9","author":"Hsu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexcr.2025.114516_bib60","first-page":"4994","article-title":"Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis","volume":"11","author":"Huang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib61","first-page":"4721","article-title":"Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis","volume":"12","author":"Wang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1453412","article-title":"Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting","volume":"14","author":"Yang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib63","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1158\/0008-5472.CAN-23-3106","article-title":"Repolarization of immunosuppressive macrophages by targeting SLAMF7-regulated CCL2 signaling sensitizes hepatocellular carcinoma to immunotherapy","volume":"84","author":"Weng","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib64","first-page":"7","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.yexcr.2025.114516_bib65","first-page":"409","article-title":"Cancer treatment and survivorship statistics","volume":"72","author":"Miller","year":"2022","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.yexcr.2025.114516_bib66","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","article-title":"Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer","volume":"27","author":"Laumont","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib67","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41375-020-01025-z","article-title":"SLAMF receptors negatively regulate B cell receptor signaling in chronic lymphocytic leukemia via recruitment of prohibitin-2","volume":"35","author":"von Wenserski","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2025.114516_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.843059","article-title":"SLAMF receptor expression identifies an immune signature that characterizes systemic lupus erythematosus","volume":"13","author":"Humbel","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib69","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/s41590-020-0770-x","article-title":"A dynamic CD2-rich compartment at the outer edge of the immunological synapse boosts and integrates signals","volume":"21","author":"Demetriou","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib70","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3802\/jgo.2024.35.e79","article-title":"SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma","volume":"35","author":"Deng","year":"2024","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1016\/j.yexcr.2025.114516_bib71","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","article-title":"Towards individualized therapy for metastatic renal cell carcinoma","volume":"16","author":"Kotecha","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.04.016","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.yexcr.2025.114516_bib73","first-page":"1","article-title":"SLAMF7 (CD319) on activated CD8+ T cells transduces environmental cues to initiate cytotoxic effector cell responses","author":"Lingel","year":"2024","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.yexcr.2025.114516_bib74","article-title":"An overview of systemic lupus erythematosus (SLE) pathogenesis, classification, and management","volume":"14","author":"Ameer","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.yexcr.2025.114516_bib75","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00011-022-01554-6","article-title":"Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus","volume":"71","author":"Bolouri","year":"2022","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40744-020-00212-9","article-title":"Systemic lupus erythematosus (SLE) therapy: the old and the new","volume":"7","author":"Basta","year":"2020","journal-title":"Rheumatology and Therapy"},{"key":"10.1016\/j.yexcr.2025.114516_bib78","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.intimp.2019.03.010","article-title":"Therapeutic advances in the treatment of SLE","volume":"72","author":"Mohamed","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.yexcr.2025.114516_bib79","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2249.2010.04116.x","article-title":"Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus","volume":"160","author":"Kim","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib80","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10875-006-9051-1","article-title":"Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B-cell tolerance loss","volume":"27","author":"Culton","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.clim.2007.10.004","article-title":"A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE","volume":"126","author":"Nicholas","year":"2008","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib82","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.4049\/jimmunol.1301022","article-title":"Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56dim NK cells","volume":"191","author":"Hagberg","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.137212","article-title":"Genetic link between gut microbiota, immune cells, and rheumatoid arthritis: mechanism of action of CD28 proteins","volume":"282","author":"Wu","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.yexcr.2025.114516_bib84","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.yexcr.2025.114516_bib85","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.yexcr.2025.114516_bib86","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3390\/cells7100161","article-title":"Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development","volume":"7","author":"Yap","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.yexcr.2025.114516_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41584-022-00790-8","article-title":"Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission","volume":"18","author":"Kurowska-Stolarska","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.yexcr.2025.114516_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abf2846","article-title":"SLAMF7 engagement superactivates macrophages in acute and chronic inflammation","volume":"7","author":"Simmons","year":"2022","journal-title":"Science immunology"},{"key":"10.1016\/j.yexcr.2025.114516_bib89","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1306584","article-title":"Role of signaling lymphocytic activation molecule family of receptors in the pathogenesis of rheumatoid arthritis: insights and application","volume":"14","author":"Zheng","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.yexcr.2025.114516_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4400","article-title":"PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis","volume":"15","author":"Woo","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.yexcr.2025.114516_bib91","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell\u2013targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2025.114516_bib92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.neuroscience.2024.04.004","article-title":"Immune system dysregulation in the progression of multiple sclerosis: molecular insights and therapeutic implications","volume":"548","author":"Khan","year":"2024","journal-title":"Neuroscience"},{"key":"10.1016\/j.yexcr.2025.114516_bib93","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13255","article-title":"The adaptation model of immunity: a new insight into aetiology and treatment of multiple sclerosis","volume":"97","author":"Manjili","year":"2023","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib94","article-title":"Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility","volume":"365","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2025.114516_bib95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/s41431-019-0569-0","article-title":"Transcript specific regulation of expression influences susceptibility to multiple sclerosis","volume":"28","author":"Ban","year":"2020","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.yexcr.2025.114516_bib96","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis","volume":"45","author":"Kemppinen","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.yexcr.2025.114516_bib97","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4049\/jimmunol.1800847","article-title":"SLAMF7 is a critical negative regulator of IFN-\u03b1\u2013Mediated CXCL10 production in chronic HIV infection","volume":"202","author":"O'Connell","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib98","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines7040184","article-title":"SLAM family receptor signaling in viral infections: HIV and beyond","volume":"7","author":"O'Connell","year":"2019","journal-title":"Vaccines"},{"key":"10.1016\/j.yexcr.2025.114516_bib99","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12974-022-02594-9","article-title":"SLAMF7 modulates B cells and adaptive immunity to regulate susceptibility to CNS autoimmunity","volume":"19","author":"O'Connell","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.yexcr.2025.114516_bib100","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00262-022-03177-6","article-title":"Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells","volume":"71","author":"Panaampon","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.yexcr.2025.114516_bib101","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/2040620716652862","article-title":"Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment","volume":"7","author":"Magen","year":"2016","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.yexcr.2025.114516_bib102","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1182\/bloodadvances.2017004382","article-title":"PD-1 blockade enhances elotuzumab efficacy in mouse tumor models","volume":"1","author":"Bezman","year":"2017","journal-title":"Blood advances"},{"key":"10.1016\/j.yexcr.2025.114516_bib103","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/leu.2013.279","article-title":"CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma","volume":"28","author":"Chu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.yexcr.2025.114516_bib104","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2025.114516_bib105","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fimmu.2015.00286","article-title":"Present and future of allogeneic natural killer cell therapy","volume":"6","author":"Lim","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib106","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexcr.2025.114516_bib107","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Chu","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.yexcr.2025.114516_bib108","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1093\/brain\/awad070","article-title":"Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis","volume":"146","author":"Lin","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.yexcr.2025.114516_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645478","article-title":"Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE","volume":"12","author":"Humbel","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib110","series-title":"AB0121 Study Of Slamf7 Expression In Primary Gougerot-Sj\u00f6gren Syndrome","author":"Schleiss","year":"2022"},{"key":"10.1016\/j.yexcr.2025.114516_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.657768","article-title":"Emerging therapeutics for immune tolerance: tolerogenic vaccines, T cell therapy, and IL-2 therapy","volume":"12","author":"Moorman","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexcr.2025.114516_bib112","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1360\/TB-2019-0806","article-title":"Advances and applications of CRISPR\/Cas toolbox","volume":"65","author":"Fang","year":"2020","journal-title":"Chin. Sci. Bull."},{"key":"10.1016\/j.yexcr.2025.114516_bib113","series-title":"Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signalling Demonstrate Efficacy and Safety in Preclinical Models of Multiple Myeloma","author":"Roders","year":"2023"}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725001120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482725001120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:23:32Z","timestamp":1762147412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482725001120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":113,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0014482725001120"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114516","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2025.114516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114516"}}